BioSpace News Archive

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has entered into a settlement agreement (the “Settlement Agreement”) with Village Farms International, Inc. (“Village Farms”) and Pure Sunfarms Corp. (“PSF,” and together with Emerald and Village Farms, the “Parties”) regarding disputes between the Parties (the “Settlement”).

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for year ended December 31, 2019 and provided an update on corporate progress.

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to AMG 594 were presented at the Keystone Symposium “Charting a New Course for Heart Failure: From Discovery to Data,” in Keystone, Colo., characterizing its mechanism of action and effect to increase cardiac contractility.

Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced preliminary unaudited net product revenue for the fourth quarter of 2019 and interim results from its Phase 1 clinical trial for OTX-TKI,

PHOENIX Rehabilitation & Health Services, has signed a definitive agreement to acquire Colorado Athletic Conditioning Clinic, expanding the company’s geographic reach to Colorado.

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will be participating in one-on-one meetings at the SunTrust Robinson Humphrey Technology, Internet and Services Conference on March 10, 2020,

Abpro to receive up to $1.1 billion, including a $30 million upfront equity investment, clinical funding, milestones, and royalties